| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_12a9e9ce63eb0bbf3658453fb50a6d9b |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2896
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2011-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c4381edb5daf5b7a172bc9169bdd28a3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3de79084abaceee7ae83dcd49ec4866e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_95cf9a9a1d228f7c01ff76ebe699c11b |
| publicationDate |
2016-12-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EA-025365-B1 |
| titleOfInvention |
APPLICATION OF ANTIBODY TO CD37 FOR TREATING A PATIENT FROM A HIGH RISK GROUP SUFFICIENT WITH CHRONIC LYMPHOLEIC LEAD (CLL), A METHOD OF DESTRUCTING EXPRESSING CD37 B CELLS IN POPULATION OF CELLS, THE DEFICIENT |
| abstract |
The invention describes antibodies to CD37, primarily A2 and B2, intended for the treatment of patients suffering from CLL, especially patients belonging to the "high risk" or "ultrahigh-risk" groups. These patients are either patients who are not susceptible to treatment with fludarabine, or patients who carry a genetic marker indicating a poor prognosis or increased risk of an adverse treatment outcome, such as patients with TP53 dysfunction or deletion of chromosome 17p13, or patients with an unfavorable outcome of previous treatment with antibodies to CD20. The ability of A2 and B2 to cause depletion of CLL cells is high in the blood samples of patients taken from normal risk and high risk patients (“high risk” patients), and pronounced exceeds the activity of rituximab and alemtuzumab. |
| priorityDate |
2010-07-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |